Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Psoriatic arthritis manifestation impairs health-related quality of life

20 Nov 2018

Psoriatic arthritis (PsA) at time of diagnosis worsens health-related quality of life (HRQOL) in comparison to the reference population, a Dutch study has found. Tender joints, enthesitis at clinical examination and back pain as indicators of pain affect HRQOL.

Of 405 patients included in the study, 320 had peripheral arthritis (78 monoarthritis, 151 oligoarthritits and 91 polyarthritis), 39 had dactylitis, 37 had enthesitis and nine had axial disease.

Mean scores of Short Form-36 (SF-36) domains were lower compared to the reference population and similar across subtypes of arthritis. Worse SF-36 scores were associated independently with a higher number of enthesitis locations and tender joints, and with the presence of chronic back pain. Moreover, psoriasis and dactylitis did not correlate with worse score.

This study analysed data collected at time of diagnosis from PsA patients included in the Dutch southwest Early Psoriatic Arthritic (DEPAR) cohort. Eight domains of the Medical Outcomes Study SF-36 questionnaire were used to assess HRQOL.

Patients were grouped according to primary manifestation in arthritis subtypes (ie, mono-, oligo- or polyarthritis) and other subtypes (ie, enthesitis, dactylitis and axial disease). The investigators determined the presence of arthritis, enthesitis, dactylitis, psoriasis and chronic inflammatory back pain in all patients. They determined associations between PsA manifestations and HRQOL using multivariable linear regression.

“PsA is a multifaceted disease. Affecting joints, skin, entheses, and dactylitis, its effect on HRQOL could be substantial,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.